Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Articles online first > Minerva Urologica e Nefrologica 2020 Feb 19

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Urologica e Nefrologica 2020 Feb 19

DOI: 10.23736/S0393-2249.20.03690-5

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Adverse events related to Radium 223 treatment: “real life” data from Eudra-Vigilance database

Giorgia TEMA 1, Riccardo LOMBARDO 1, Olivia VOGLINO 1, Angela SICA 1, Valeria BALDASSARRI 1, Antonio NACCHIA 1, Roberto IACOVELLI 2, Andrea TUBARO 1, Cosimo DE NUNZIO 1

1 Department of Urology, Ospedale Sant’Andrea, Rome, Italy; 2 Oncologia Medica, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy


PDF


BACKGROUND: Aim of our study was to analyze adverse events (AEs) associated with Radium 223 using real life data from Eudra-Vigilance (EV) database.
METHODS: EV database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA). We recorded number of AEs for Radium 223 per category and severity from 2013 to May 2019. We recorded AEs per age group (<65 years old; between 65 and 85 years; >85 years old) Pooled Relative Risk (PRR) were used to compare groups. The number of individual cases identified in EV database was 4339.
RESULTS: According to the registry study the most frequent AEs in patients treated with Radium 223 were hematological, general and gastrointestinal disorders and they were confirmed as the most frequent AEs in the EV database. In the EV database over 90% of the reported AEs were defined as serious and 8% were fatal. Older patients (>85 years) treated with Radium 223 were at increased risk of cardiac, infectious, and metabolism disorders when compared to younger patients (<65). However, we have no information on the number of patients under treatment in the EV database.
CONCLUSIONS: EV database highlights several AEs which are not reported in registry studies as well as different AEs profiles according to age. Clinicians should consider these data when treating patients with Radium 223.


KEY WORDS: Eudravigilance; Radium 223; Real-life; Adverse events

top of page